Overview

* Milestone Q3 2025 reports no revenue, net loss of $11.9 mln

* Company prepares for CARDAMYST launch pending FDA approval in December

* Milestone strengthens finances with equity offering and royalty agreement

Outlook

* Milestone plans quick launch of CARDAMYST following potential FDA approval

* Company expects $75 mln royalty payment upon CARDAMYST FDA approval

* Milestone poised to enter Phase 3 program for etripamil in AFib-RVR

Result Drivers

* COMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal spray

* FINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launch

* CLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVT

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Basic -$0.12

EPS

Q3 -$11.83

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc ( MIST ) is $4.00, about 52.3% above its November 11 closing price of $1.91

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)